TrialChild psychiatry and human development2023

A Phase III Study of Bumetanide Oral Liquid Formulation for the Treatment of Children and Adolescents Aged Between 7 and 17 Years with Autism Spectrum Disorder (SIGN 1 Trial): Participant Baseline Characteristics.

Christina Georgoula et al.PubMed ↗Publisher ↗

No numbers read from the abstract.